CN111184748A - 一种改善肌肉萎缩的微生物菌剂及其应用 - Google Patents
一种改善肌肉萎缩的微生物菌剂及其应用 Download PDFInfo
- Publication number
- CN111184748A CN111184748A CN202010084509.4A CN202010084509A CN111184748A CN 111184748 A CN111184748 A CN 111184748A CN 202010084509 A CN202010084509 A CN 202010084509A CN 111184748 A CN111184748 A CN 111184748A
- Authority
- CN
- China
- Prior art keywords
- muscle
- veillonella
- ruminococcus
- muscle atrophy
- microbial agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000585 muscular atrophy Diseases 0.000 title claims abstract description 44
- 230000000813 microbial effect Effects 0.000 title claims abstract description 22
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 36
- 241001148134 Veillonella Species 0.000 claims abstract description 33
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 32
- 241000192031 Ruminococcus Species 0.000 claims abstract description 30
- 210000003205 muscle Anatomy 0.000 claims abstract description 28
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims 5
- 241000305071 Enterobacterales Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 24
- 230000006872 improvement Effects 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 235000021120 animal protein Nutrition 0.000 description 6
- 238000010219 correlation analysis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241001478240 Coccus Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004767 rumen Anatomy 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000588748 Klebsiella Species 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 3
- 241001057811 Paracoccus <mealybug> Species 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 241000605947 Roseburia Species 0.000 description 2
- 241001608455 Rossia <Bacillariophyta> Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 235000021196 dietary intervention Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940071440 soy protein isolate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000025161 regulation of muscle atrophy Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了改善肌肉萎缩的微生物菌剂及其应用,涉及肠道菌应用技术领域。本发明所述微生物菌剂包括肠道菌,所述肠道菌包括瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella),经验证肠道中的瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella),这两种菌都可以改善肌肉萎缩症状,增加肌肉面积,提高肌肉抓持力,且与肌肉萎缩的改善呈现显著的正向关联,可用于改善肌肉萎缩症状。
Description
技术领域
本发明属于肠道菌应用技术领域,具体涉及一种改善肌肉萎缩的微生物菌剂及其应用。
背景技术
骨骼肌占体重的40%左右,在维持人体健康方面起着至关重要的作用,包括氨基酸和葡萄糖代谢、蛋白质储存和运动。肌肉萎缩是现代社会人们普遍面临的一种慢性代谢性疾病,长期缺乏运动、老年人、癌症患者以及大剂量激素治疗人群都会面临不同程度的肌肉萎缩。研究表明肌肉萎缩已经成为影响死亡的独立因素。因此,如何有效改善肌肉萎缩的已经成为亟待解决的健康问题。
以往研究主要是从细胞信号传导途径的角度对肌肉萎缩的机制进行研究。遗憾的是到目前为止仍然无法筛选出“既能阻断调控肌肉萎缩相关的细胞信号传导通路,又不会产生新的负作用”的药物。因此亟待寻找新的改善途径。由于人类肠道菌群是一个复杂的生态***,它可以通过食物复合物的生物转化影响营养物质的吸收,同时它们的代谢产物可以通过肠道紧密连接进入血液循环,进入肌肉组织。这些研究线索提示肠道菌群可能是调控肌肉萎缩的一个有效靶点。然而目前尚没有相关研究去寻找能够改善肌肉萎缩的肠道微生物菌株。
发明内容
有鉴于此,本发明的目的在于提供一种改善肌肉萎缩的微生物菌剂及其应用,使得肠道菌群可作为调控肌肉萎缩的一个有效靶点,改善肌肉萎缩症状,改良肌肉面积,提高肌肉抓持力。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种改善肌肉萎缩的微生物菌剂,所述微生物菌剂包括肠道菌,所述肠道菌包括瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella)。
本发明还提供了一种改善肌肉萎缩的营养补充剂,包括所述微生物菌剂。
本发明还提供了所述微生物菌剂或所述营养补充剂在制备改良肌肉面积的营养品中的应用。
本发明还提供了所述微生物菌剂或所述营养补充剂在制备提高肌肉抓持力的营养品中的应用。
本发明提供了一种改善肌肉萎缩的微生物菌剂,所述微生物菌剂包括肠道菌中的瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella)。本发明通过临床队列的方法从长期肌肉萎缩的造血干细胞移植患者的粪便内筛选得到所述肠道菌;然后将所述肠道益生菌的丰度值大小与对应肌肉萎缩改善程度进行关联分析,发现瘤胃球菌(Ruminococcus)与肌肉面积改良的相关系数达0.65(p=0.2),与肌肉抓持力的相关系数为0.78(p=0.06);韦荣氏球菌(veillonella)与肌肉面积改良的相关系数达0.75(p=0.08),与肌肉抓持力的相关系数为0.55(p=0.25)。因此瘤胃球菌(Ruminococcus)和韦荣氏球菌(veillonella)与肌肉萎缩的改善呈现显著的正向关联,可用于改善肌肉萎缩症状。
附图说明
图1为瘤胃球菌(Ruminococcus)与肌肉面积改良的相关性分析图;
图2为瘤胃球菌(Ruminococcus)与肌肉抓持力的相关性分析图;
图3为韦荣氏球菌(veillonella)与肌肉面积改良的相关性分析图;
图4为韦荣氏球菌(veillonella)与肌肉抓持力的相关性分析图;
图5为肠道益生菌的筛选流程图。
具体实施方式
本发明提供了改善肌肉萎缩的微生物菌剂,所述微生物菌剂包括肠道菌,所述肠道菌包括瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella)。
本发明对所述瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella)的来源并没有任何限定,可购买常规市售菌株(菌系),也可自肠道或肠道***物中提取。本发明实施例中为说明所述肠道菌的效果,优选按照如图5所示流程,从长期肌肉萎缩的造血干细胞移植患者的肠道***物中筛选得到。本发明在所述筛选前优选还包括对所述患者进行为期两个月的优质蛋白质营养干预,所述干预优选包括摄入热量35kcal/kg/d,摄入蛋白质1.5g/kg/d;其中蛋白质包括动物蛋白和植物蛋白,且动物蛋白与植物蛋白的质量比为1:1。本发明所述动物蛋白优选包括大豆蛋白分离物,所述大豆蛋白分离物优选购自禹王集团(货号YP928H,山东,中国)。本发明所述动物蛋白优选包括乳清蛋白,所述乳清蛋白优选购自Livingston(Hilmar9410,Livingston,CA,USA)。本发明优选将经过所述干预后的患者通过肌肉CT扫描判断肌肉萎缩改善效果,并按照肌肉改善效果的好坏分为两组(肌肉萎缩改善人群和没有改善人群),分别将两组人群蛋白干预前后的肠道微生物标本进行16srDNA测序。本发明在所述测序后,利用UCLUST,在97%的一致性阈值下,将该序列集划分为可操作的分类单元(OTU),使用GLSEARCH程序通过相似度对每个OTU进行分类分配;然后利用Metastats分析(组间显著性差异分析),该分析通过对比肌肉萎缩改善人群以及没有改善人群中肠道菌群丰度前20%的肠道菌株,在通过组间差异分析寻找出具有显著统计学差异的菌株,即肠球菌(Enterococcus)、韦荣氏球菌(Veillonella)、瘤胃球菌(Ruminococcus)、类杆菌(Bacteroides)、克雷伯氏菌(Klebsiella)、黄酮类杆菌(Flavonifractor)、梭杆菌(Fusobacterium)、副球菌(Parasutterella)、链球菌(Streptococcus)和罗斯氏菌(Roseburia);最后将这些差异菌按照其丰度值大小与对应肌肉萎缩改善程度进行关联分析,发现瘤胃球菌(Ruminococcus)和韦荣氏球菌(veillonella)与肌肉萎缩的改善呈现显著的正向关联。
本发明还提供了一种改善肌肉萎缩的营养补充剂,包括所述微生物菌剂。本发明所述营养补充剂可对改善肌肉萎缩患者进行营养干预,从而促进其肌肉面积增大和提高肌肉抓持力。
本发明还提供了所述微生物菌剂或所述营养补充剂在制备改良肌肉面积的营养品中的应用。本发明所述营养品中优选还包括常规的食用级辅料。
本发明还提供了所述微生物菌剂或所述营养补充剂在制备提高肌肉抓持力的营养品中的应用。本发明所述应用优选与上述相同,在此不再赘述。
下面结合实施例对本发明提供的改善肌肉萎缩的微生物菌剂及其应用进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
采用了临床队列(Cohort study)的方法进行本实施例方案。本发明实施例经由中国临床注册中心注册(ChiCTR 1800017765)。
按照如图5所示流程进行筛选:通过招募长期肌肉萎缩的造血干细胞移植患者,并且通过对所有入组人群进行为期两个月的优质蛋白质营养干预(摄入热量35kcal/kg/d,摄入蛋白质1.5g/kg/d;其中蛋白质由动物蛋白和植物蛋白按1:1的质量比组成,其中植物蛋白为大豆蛋白分离物(YP928H,禹王集团,山东,中国),动物蛋白为乳清蛋白(Hilmar9410,Livingston,CA,USA))。两个月后通过肌肉CT扫描判断肌肉萎缩改善效果。之后,将入组人群按照肌肉改善效果的好坏分为两组(患者干预后肌肉CT扫描和握力值,通过计算干预前后CT肌肉面积变化和握力变化的差值,将两种指标的差值均为正值的列为肌肉改善组;将两组指标差值均为负的列为肌肉萎缩没有改善组),分别将两组人群蛋白干预前后的肠道微生物标本进行16srDNA测序。
肠道菌群16srDNA分析方法:
从解冻的粪便样本中提取DNA。用2%琼脂糖凝胶电泳和分光光度法测定DNA质量。用FastPfu DNA聚合酶(TransStartTM,TransGen Biotech)扩增16srDNA基因的V3-V4区。
引物采用336F(SEQ ID NO.1):5'-GTACTCCTAGGGGGCAGCA-3';
806R(SEQ ID NO.2):5'-GTGGACTACHVGGGTWTCTAAT-3'。
PCR循环条件如下:95℃预变性5min;85℃变性45s,55℃退火50s,72℃延伸45s,28个循环;72℃延长10min。
纯化的扩增子以等摩尔量汇集,根据标准方案在Illumina MiSeq平台上进行成对末端测序(2×300)。利用UCLUST,在97%的一致性阈值下,将该序列集划分为可操作的分类单元(otu)。使用GLSEARCH程序通过相似度对每个OTU进行分类分配,共得到1311239个高质量序列,覆盖率在99%以上。采用RDP Classifier算法(默认)或blast、uclust consensustaxonomy assigner等方法对OTU代表序列进行比对分析,并在各个水平(界、门、纲目、科、属、种)注释其群落的物种信息。
瘤胃球菌(Ruminococcus)和韦荣氏球菌(veillonella)与肌肉萎缩改善的研究方法:
利用Metastats分析,即组间显著性差异分析。该分析通过对比肌肉萎缩改善人群以及没有改善人群中肠道菌群丰度前1/5的肠道菌株,在通过组间差异分析寻找出具有显著统计学差异的菌株,即肠球菌(Enterococcus)、韦荣氏球菌(Veillonella)、瘤胃球菌(Ruminococcus)、类杆菌(Bacteroides)、克雷伯氏菌(Klebsiella)、黄酮类杆菌(Flavonifractor)、梭杆菌(Fusobacterium)、副球菌(Parasutterella)、链球菌(Streptococcus)和罗斯氏菌(Roseburia);最后将这些差异菌按照其丰度值大小与对应肌肉萎缩改善程度进行关联分析(结果见图1~图4),发现瘤胃球菌(Ruminococcus)和韦荣氏球菌(veillonella)与肌肉萎缩的改善呈现显著的正向关联。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 农业农村部食物与营养发展研究所
<120> 一种改善肌肉萎缩的微生物菌剂及其应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
gtactcctag ggggcagca 19
<210> 2
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gtggactach vgggtwtcta at 22
Claims (4)
1.一种改善肌肉萎缩的微生物菌剂,其特征在于,所述微生物菌剂包括肠道菌,所述肠道菌包括瘤胃球菌(Ruminococcus)和/或韦荣氏球菌(veillonella)。
2.一种改善肌肉萎缩的营养补充剂,其特征在于,包括权利要求1所述微生物菌剂。
3.权利要求1所述微生物菌剂或权利要求2所述营养补充剂在制备改良肌肉面积的营养品中的应用。
4.权利要求1所述微生物菌剂或权利要求2所述营养补充剂在制备提高肌肉抓持力的营养品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010084509.4A CN111184748A (zh) | 2020-02-10 | 2020-02-10 | 一种改善肌肉萎缩的微生物菌剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010084509.4A CN111184748A (zh) | 2020-02-10 | 2020-02-10 | 一种改善肌肉萎缩的微生物菌剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111184748A true CN111184748A (zh) | 2020-05-22 |
Family
ID=70686159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010084509.4A Pending CN111184748A (zh) | 2020-02-10 | 2020-02-10 | 一种改善肌肉萎缩的微生物菌剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111184748A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
US20180255821A1 (en) * | 2017-03-10 | 2018-09-13 | International Nutrition Research Company | Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases |
CN109310715A (zh) * | 2016-04-11 | 2019-02-05 | 哈佛学院董事及会员团体 | 用于促进运动表现的益生菌制剂 |
-
2020
- 2020-02-10 CN CN202010084509.4A patent/CN111184748A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
CN109310715A (zh) * | 2016-04-11 | 2019-02-05 | 哈佛学院董事及会员团体 | 用于促进运动表现的益生菌制剂 |
US20180255821A1 (en) * | 2017-03-10 | 2018-09-13 | International Nutrition Research Company | Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases |
Non-Patent Citations (3)
Title |
---|
夏亚丽: "益生菌对老年人健康促进作用的机制研究进展", 《中国营养学会第十四届全国营养科学大会暨第十一届亚太临床营养大会》 * |
焦金真 等: "浏阳黑山羊胃肠道不同部位重要功能微生物的数量分布特征研究 ", 《畜牧兽医学报》 * |
高键,葛声主编: "《吃对就健康》", 31 January 2010, 上海科学技术文献出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Intestinal microbiota of gibel carp (Carassius auratus gibelio) and its origin as revealed by 454 pyrosequencing | |
Janczyk et al. | Microbial community composition of the crop and ceca contents of laying hens fed diets supplemented with Chlorella vulgaris | |
Hammons et al. | A small variation in diet influences the Lactobacillus strain composition in the crop of broiler chickens | |
Matsui et al. | Microbial diversity in ostrich ceca as revealed by 16S ribosomal RNA gene clone library and detection of novel Fibrobacter species | |
CN102549162B (zh) | 用于改善反刍动物健康和/或性能的菌株和方法 | |
De Cesare et al. | Effect of a low protein diet on chicken ceca microbiome and productive performances | |
US11951138B2 (en) | Microbial compositions comprising rumen microflora and uses thereof | |
CN1272877A (zh) | 饲料产品 | |
US20040101860A1 (en) | Predicting animal performance | |
CN102823772A (zh) | 一种抗猪热应激的富硒复合菌饲料添加剂及其应用 | |
Mao et al. | Use of pyrosequencing to characterize the microbiota in the ileum of goats fed with increasing proportion of dietary grain | |
CN108522884B (zh) | 一种复合微生态制剂用于预防肉鸡脂肪沉积的用途 | |
Zhu et al. | Comparative study of the bacterial communities throughout the gastrointestinal tract in two beef cattle breeds | |
Hong et al. | Bacterial diversity at different sites of the digestive tract of weaned piglets fed liquid diets | |
Guo et al. | Enhanced intestinal microflora composition and phosphorus-transportation efficiency in fast-growing spotted seabass (Lateolabrax maculatus) fed a low-phosphorus diet | |
Wang et al. | Comparative analysis of the intestinal microbiota in goldfish and crucian carps between different aquaponics and traditional farming | |
CN111184748A (zh) | 一种改善肌肉萎缩的微生物菌剂及其应用 | |
Wang et al. | Effects of Phragmites australis shoot remainder silage on growth performance, blood biochemical parameters, and rumen microbiota of beef cattle | |
CN115820458B (zh) | 具有缓解溃疡性结肠炎功效的长双歧杆菌050101及其应用 | |
Enoka et al. | Effect of garlic and onion extract chitosan nanoparticles on selected intestinal bacterial flora in indigenous rainbow rooster chicken in Kenya. | |
CN111117935A (zh) | 一种抑制肌肉合成的微生物菌剂及其应用 | |
Wang et al. | Fermentation profile and microbial diversity of temperate grass silage inoculated with epiphytic microbiota from tropical grasses | |
CN114786494A (zh) | 微生物组干预 | |
KR102169139B1 (ko) | 삼채 잎의 분말을 유효성분으로 포함하는 가금류의 장내 균총 개선용 조성물 | |
JP2021506340A (ja) | 水添加剤及び組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200522 |
|
RJ01 | Rejection of invention patent application after publication |